Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/13/2845843/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Announces-Fourth-Quarter-and-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/07/2842739/0/en/Quoin-Pharmaceuticals-Announces-Fourth-Quarter-and-2023-Financial-Results-and-Corporate-Update-Conference-Call-to-be-held-on-Thursday-March-14th-at-8-30-am-ET.html
https://www.globenewswire.com//news-release/2024/03/05/2840412/0/en/Quoin-Pharmaceuticals-Announces-Pricing-of-6-5-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/03/04/2839532/0/en/Quoin-Pharmaceuticals-Announces-FDA-Clearance-to-Recruit-Teen-Subjects-into-Both-Ongoing-Netherton-Syndrome-Clinical-Studies.html
https://www.globenewswire.com//news-release/2024/02/08/2825976/0/en/Quoin-Pharmaceuticals-Files-U-S-and-International-Patent-Applications-for-Novel-Netherton-Syndrome-Combination-Product.html
https://www.globenewswire.com//news-release/2023/12/13/2795561/0/en/Quoin-Pharmaceuticals-Announces-FDA-Clearance-of-Clinical-Optimization-Plan-for-QRX003-for-Netherton-Syndrome.html
https://www.globenewswire.com//news-release/2023/11/08/2776844/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Announces-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/11/03/2773195/0/en/Quoin-Pharmaceuticals-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Update-Conference-Call-to-be-held-on-Thursday-November-9th-at-8-30-am-ET.html
https://www.globenewswire.com//news-release/2023/10/24/2765741/0/en/REPEAT-Quoin-Pharmaceuticals-Announces-Additional-Positive-Clinical-Data-from-Open-Label-Single-Arm-Clinical-Trial-in-Netherton-Syndrome.html
https://www.globenewswire.com//news-release/2023/10/24/2765613/0/en/Quoin-Pharmaceuticals-Announces-Additional-Positive-Clinical-Data-from-Open-Label-Single-Arm-Clinical-Trial-in-Netherton-Syndrome.html